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due to oral antibacterial switching in cSSTIs. Increased use of linezolid in the treat-
ment of MRSA-cSSTIs could result in substantial savings for the Greek hospital budget.
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Objectives: Ventilator-associated pneumonia(VAP) is a serious complication risk 
for patients who require invasive mechanical ventilation(IMV). VAP is associated 
with longer intensive care unit and hospital stays, which may increase health care 
expenditures. VAP may occur in 8% of IMV patients. Subglottic aspiration (SA) may 
decrease VAP by up to 45% in IMV patients. The goal of this analysis is to calculate 
the potential cost reduction associated with SA use for VAP reduction in IMV patients 
in Turkey. MethOds: A literature analysis was conducted in PubMed(2000-present) 
to determine the published cost of VAP in Turkey. Published costs were used for the 
conversion to Turkish Lira(TL). An annual inflation rate of 3% was applied to the cost 
data to project the estimated cost in 2013. The exchange rate for USD to TL was esti-
mated at 1.8. A weighted average of the number of patients in each study was used to 
calculate the cost of treatment. The cost of SA to the Social Security Institution (SGK) 
was calculated as 33.94 TL, which includes the cost of the SA tube(TaperGuard EVAC; 
25 TL) and the SA service reimbursement amount from the SGK of 8.94 TL. 8% and 
45% were taken as the VAP rate and reduction with SA rate in IMV patients, respec-
tively. The number of patients requiring IMV in a hospital was estimated at 1000 per 
year. Results: The average inpatient costs of IMV patients with and without VAP were 
calculated to be 13.556 TL and 3.971 TL, respectively. The total VAP cost, based on 80 VAP 
cases in 1,000 IMV cases without SA, was calculated as 1.085.297 TL. A hospital using 
SA for all IMV cases is estimated to have VAP costs equal to 488.384 TL and SA costs of 
33.940 TL for a total cost of 522.324 TL. Cost reduction from SA use was calculated as 
562.973 TL. cOnclusiOns: VAP increases health expenditures by 9.595 TL per patient. 
A hospital with 1,000 IMV patients per year that uses SA in all IMV patients may realize 
an estimated cost reduction of 562.973 TL associated with use of SA in IMV patients.
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Objectives: Treatment options for chronic hepatitis B (CHB) are the direct inhibi-
tion of viral replication by continuous administration of nucleosides analogues 
(NUCs) or a finite 48-weeks course of peg-interferon (PEG). PEG can induce the 
off-therapy immune control of CHB leading to HBsAg loss/anti-HBs seroconver-
sion but at a low success rate. On the other hand life-long treatment with NUCs is 
expensive. Exploiting the early identification of PEG-non-responders by combined 
HBV-DNA and HBsAg quantification at week-12 (stopping-rule), a new sequential 
therapeutic strategy may benefit both patients and payers. We measured the impact 
on the Italian National Health Service budget using the PEG-week-12-stopping-
rule in the treatment of HBeAg-negative CHB. MethOds: A Markov model was 
developed over a 5 year horizon in the states: CHB, virologic response, relapse, 
HBsAg clearance, compensated and decompensated cirrhosis, hepatocarcinoma, 
liver transplant, post-liver transplant and death. The target population (treatment 
naïve CHB patients) was determined based on Italian national population forecasts 
and epidemiological data. The current mix of treatment with NUCs (entecavir, teno-
fovir, adefovir, lamivudine and telbivudine) and PEG (with no stopping rule) was 
compared with a mix based on a hypothetical uptake of PEG (with the stopping rule). 
The percentage of uptake from NUCs started at 25%, increasing over time. Results: 
The estimated impact on the Italian NHS budget, over 5 years of treatment, resulted 
in a saving of approximately € 74 million, 95% of which accounted for drug cost. The 
beneficial impact of the stopping-rule became clear from the second year, when a 
break-even point was reached. cOnclusiOns: The large estimated savings in drug 
costs following the uptake of PEG + stopping-rule in the treatment of CHB HBeAg 
negative patients, together with previously published cost-effectiveness results, 
demonstrate a potentially advantageous profile of such a strategy, that could allow 
for more efficient use of health care resources.
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Objectives: Vaccination is a cost-effective intervention; however limited infra-
structure in developing countries can pose significant challenges in efficient vac-
cine delivery. Countries prefer multidose presentations due to lower acquisition 
and cold chain costs, but open vial vaccine wastage is a major part of program 
cost. The aim of this study was to examine country-level factors that impact open 
vial wastage. MethOds: A demographics-based budget impact model with a 10 
year time horizon was developed in Excel v14 using Palisade’s @Risk v6.0 software. 
The model estimated daily vaccine utilization and wastage rates for Pentavalent, 
Pneumococcal, HPV and IPV using Lee’s (2010) model, calibrated to arrival distri-
butions based on field data session sizes from Bangladesh, Mozambique, India 
(Uttar Pradesh), and Uganda. The statistical distribution was determined using 
maximum likelihood, stratified by urban/rural for each clinic type. The model 
ran 1000 iterations, with each drawing independently from the statistical distri-
butions of session sizes by clinic type. Results: The negative binomial family 
offered the best fit to session size by Akaike Information Criterion. The leading 
improved medication adherence, better virologic suppression, lower hospitalization 
rates, and lower health care costs. The objective of this study was to estimate the 
budget impact to a US health care plan of the use of EVG/COBI/FTC/TDF in adults 
with HIV who are treatment-naïve or currently on treatment with no resistance to 
the components of EVG/COBI/FTC/TDF. MethOds: The model estimates total direct 
health care costs associated with HIV management before and after the introduction 
of EVG/COBI/FTC/TDF. HIV epidemiology, hospitalization rates, and adverse event 
incidence and their associated costs were calculated using results of published 
studies or publically available sources. Regimen utilization was obtained from recent 
chart audit analysis and EVG/COBI/FTC/TDF market share was projected to come 
from protease inhibitor (PI)-based regimens in relative proportion to each regimen’s 
market share. The budget impact was calculated annually and cumulatively over 
a 3-year period without discounting, following standard methodology for budget 
impact analyses. Results: For a hypothetical health care plan with 1 million mem-
bers, the model estimated 450 HIV-positive members currently on treatment and 
72 HIV-positive members initiating HIV therapy each year. Over a 3-year period, 
the introduction of EVG/COBI/FTC/TDF was expected to result in greater use of 
single tablet regimens and lower use of more expensive PI-based regimens, yielding 
lower pharmacy costs ($226,194, 0.5% lower), fewer hospitalizations (1.1% fewer), and 
lower hospitalization costs ($31,288, 1.1% lower) versus scenario without EVG/COBI/
FTC/TDF. Total cost savings over 3 years were estimated at $240,375 (0.4% lower), 
equivalent to a reduction in per-member-per-month (PMPM) costs from $1.61 to 
$1.60. PMPM results were insensitive to changes in parameters. cOnclusiOns: 
The introduction of EVG/COBI/FTC/TDF is expected to result in fewer hospitaliza-
tions with a negligible impact on pharmacy and total costs over a 3-year period for 
a US health care plan.
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Objectives: Two meta-analyses associated with a public health model demon-
strated that probiotics (live microorganisms which when administered in adequate 
amount confer a health benefit on the host) have an important public health impact: 
they reduce upper respiratory tract infection (URTI) episodes with less antibiotics 
and sick leave prescriptions, in France. This analysis reports the budget impact for 
the National Health System (NHS) and the Nation. MethOds: The public health 
impact model (1/1,000 virtual age-gender standardized population generated with 
a Markov model: 1-day cycles, 2011-2012 winter period, URTI incidence from a 
General Practitioner [GP] network) was used. Economic perspectives were society, 
NHS and family. The analysis was limited to patients having visited a GP. Resource 
utilization came from the GP network. Unit costs were applied: Ameli.fr for drugs, 
Classification Commune des Actes Médicaux for GP visits, gross domestic product 
(GDP)/capita or allowances for sick leaves. Outcomes included direct medical and 
indirect costs. Results were reported according to each meta-analysis, Cochrane 
and York Health Economics Consortium (YHEC). Results: The economic impact 
of probiotics was about € 95 million saved from the Society perspective according 
to YHEC (Family: -€ 21.7 million; NHS: -€ 15.4 million) and € 229.1 million according 
to Cochrane (Family: -€ 130.4 million; NHS: -€ 34.6 million). Absenteeism was the 
main driver for the society perspective representing 98% (YHEC) or 78% (Cochrane) 
of the savings. For the NHS, the main driver was sick leave (94%, YHEC-based) or 
GP visit (67%, Cochrane-based): avoiding URTI episodes (Cochrane) generates more 
visit savings than reducing disease duration (YHEC). More savings were observed 
in children, active smokers and people with more human contacts compared to 
the general population. cOnclusiOns: Probiotics savings are substantial, whether 
they reduce URTI episodes frequency or duration. Noteworthy, 2011-12 winter URTI 
incidence rate was low and this analysis focused on the 1% URTI accessing the NHS.
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Objectives: Meticillin-resistant staphylococcus aureus (MRSA) is an important cause 
of antimicrobial-resistant health care-associated infections worldwide. Its prevalence 
remains high in the Greek hospital setting. Complicated skin and soft tissue infections 
(cSSTIs) due to MRSA are associated with prolonged hospitalization, additional costs 
of care and significant morbidity. The purpose of this study was to conduct a budget 
impact analysis relative to different management scenarios for MRSA-cSSTIs from 
a hospital perspective. MethOds: Equal efficacy for the pharmacotherapies under 
evaluation was assumed and resource use was elicited via an expert panel. The model 
was based on a decision tree for the management of hospitalized patients with MRSA-
cSSTIs, simulating costs and outcomes for the duration of hospitalization according 
to the therapeutic scenario, including empiric and first-line therapies. Inpatient costs 
consisted of hospitalization, diagnostic, medical and antibiotic costs. Economic results 
(Euros 2013) reflect the hospital setting. Results: Total per patient cost according to 
first-line agent was € 2,458, € 2,730, € 2,850, € 3,495 and € 3,098 and mean length of stay 
(LOS) was 9.2, 12.5, 10.3, 13.0 and 14.0 days for linezolid, vancomycin, daptomycin, tige-
cyline, teicoplanin respectively. An estimated 10,287 MRSA-cSSTI patients are treated 
annually in Greek hospitals. Thus, by increasing the use of linezolid by 11% over a 
three-year period, for the management of MRSA-cSSTIs, this could result in savings of 
€ 331,602 for the hospital budget (current:€ 29,081,597, projected:€ 28,749,994). By reduc-
ing the LOS for linezolid patients from 9.2 days (current LOS in Greece as per expert 
panel) to 7.6 days to match data from a large phase IV study in MRSA-cSSTIs (Itani 2010), 
potential savings amount to € 808,673. cOnclusiOns: The analysis corroborates litera-
ture findings with regards to the early switch/early discharge potential and outcomes 
